Literature DB >> 21296315

Comparison of inhaled nitric oxide versus oxygen on hemodynamics in patients with mitral stenosis and severe pulmonary hypertension after mitral valve surgery.

Juliano L Fernandes1, Roney O Sampaio, Carlos M Brandão, Tarso Augusto D Accorsi, Luiz F Cardoso, Guilherme S Spina, Flavio Tarasoutchi, Pablo Pomerantzeff, Jose O Auler, Max Grinberg.   

Abstract

Pulmonary hypertension represents an important cause of morbidity and mortality in patients with mitral stenosis who undergo cardiac surgery, especially in the postoperative period. The aim of this study was to test the hypothesis that inhaled nitric oxide (iNO) would improve the hemodynamic effects and short-term clinical outcomes of patients with mitral stenosis and severe pulmonary hypertension who undergo cardiac surgery in a randomized, controlled study. Twenty-nine patients (4 men, 25 women; mean age 46 ± 2 years) were randomly allocated to receive iNO (n = 14) or oxygen (n = 15) for 48 hours immediately after surgery. Hemodynamic data, the use of vasoactive drugs, duration of stay, and short-term complications were assessed. No differences in baseline characteristics were observed between the groups. After 24 and 48 hours, patients receiving iNO had a significantly greater increase in cardiac index compared to patients receiving oxygen (p <0.0001). Pulmonary vascular resistance was also more significantly reduced in patients receiving iNO versus oxygen (-117 dyne/s/cm(5), 95% confidence interval -34 to -200, vs 40 dyne/s/cm(5), 95% confidence interval -34 to 100, p = 0.005) at 48 hours. Patients in the iNO group used fewer systemic vasoactive drugs (mean 2.1 ± 0.14 vs 2.6 ± 0.16, p = 0.046) and had a shorter intensive care unit stay (median 2 days, interquartile range 0.25, vs median 3 days, interquartile range 7, p = 0.02). In conclusion, iNO immediately after surgery in patients with mitral stenosis and severe pulmonary hypertension improves hemodynamics and may have short-term clinical benefits.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296315     DOI: 10.1016/j.amjcard.2010.11.030

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Inhaled pulmonary vasodilators: a narrative review.

Authors:  Kai Liu; Huan Wang; Shen-Ji Yu; Guo-Wei Tu; Zhe Luo
Journal:  Ann Transl Med       Date:  2021-04

Review 2.  Pharmacologic management of perioperative pulmonary hypertension.

Authors:  Julie W Cheng; Adriano R Tonelli; Gosta Pettersson; Richard A Krasuski
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

Review 3.  Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials.

Authors:  Sheng-Yuan Ruan; Tao-Min Huang; Hon-Yen Wu; Huey-Dong Wu; Chong-Jen Yu; Mei-Shu Lai
Journal:  Crit Care       Date:  2015-04-03       Impact factor: 9.097

Review 4.  Inhaled therapy for the management of perioperative pulmonary hypertension.

Authors:  C A Thunberg; S T Morozowich; Harish Ramakrishna
Journal:  Ann Card Anaesth       Date:  2015 Jul-Sep

Review 5.  Postoperative Right Ventricular Failure in Cardiac Surgery.

Authors:  Victor H Nieto Estrada; Daniel L Molano Franco; Albert A Valencia Moreno; Jose A Rojas Gambasica; Cristian C Cortes Nunez
Journal:  Cardiol Res       Date:  2016-12-31

Review 6.  Acute Right Ventricular Dysfunction in Intensive Care Unit.

Authors:  Juan C Grignola; Enric Domingo
Journal:  Biomed Res Int       Date:  2017-10-19       Impact factor: 3.411

7.  Effect of nitric oxide on postoperative acute kidney injury in patients who underwent cardiopulmonary bypass: a systematic review and meta-analysis with trial sequential analysis.

Authors:  Jie Hu; Stefano Spina; Francesco Zadek; Nikolay O Kamenshchikov; Edward A Bittner; Juan Pedemonte; Lorenzo Berra
Journal:  Ann Intensive Care       Date:  2019-11-21       Impact factor: 6.925

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.